


Gilead: Stopping NUCs in HBV Cure Trials

Goal

Finite therapy leading to functional cure, defined as durable loss of serum HBsAg



*Proportion of subjects who achieve functional cure, defined as HBsAg loss and HBV DNA <20 IU/mL

